PharVision Advisers’s Eli Lilly LLY Stock Holding History

PharVision Advisers’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-260	Closed	-$279K	–	405
2025 Q4	$279K	Buy	+260	New	+$249K	0.14%	311

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PharVision Advisers's LLY Position: Q1 2026 in Review

PharVision Advisers sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 260 shares — an estimated $279K sold.

PharVision Advisers first reported a position in LLY in Q4 2025 and held it in 1 quarter. The position peaked at $279K in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

PharVision Advisers reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 260 Eli Lilly shares in Q1 2026, an estimated $279K.
PharVision Advisers first reported a position in Eli Lilly in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Eli Lilly position peaked at $279K in Q4 2025.
4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.